Humacyte (NASDAQ:HUMA) Stock Rating Upgraded by Wall Street Zen

Humacyte (NASDAQ:HUMA - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Friday.

A number of other brokerages also recently issued reports on HUMA. D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of Humacyte in a research report on Monday, June 9th. Benchmark reduced their price target on Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Finally, HC Wainwright began coverage on Humacyte in a report on Wednesday, May 14th. They issued a "buy" rating and a $4.00 price target on the stock. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $11.71.

Humacyte Trading Down 4.5%

HUMA stock traded down $0.10 during midday trading on Friday, reaching $2.12. 7,258,429 shares of the company traded hands, compared to its average volume of 3,838,927. Humacyte has a 52-week low of $1.15 and a 52-week high of $9.79. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.28 and a current ratio of 3.68. The business has a 50 day moving average of $2.06 and a 200-day moving average of $3.01. The firm has a market capitalization of $328.85 million, a price-to-earnings ratio of -3.07 and a beta of 2.00.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.09. The company had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.46 million. As a group, sell-side analysts expect that Humacyte will post -1.27 earnings per share for the current fiscal year.

Insider Transactions at Humacyte

In other news, CFO Dale A. Sander acquired 20,000 shares of Humacyte stock in a transaction on Thursday, April 10th. The shares were bought at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the acquisition, the chief financial officer now directly owns 40,600 shares of the company's stock, valued at $62,118. This trade represents a 97.09% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Kathleen Sebelius acquired 50,000 shares of Humacyte stock in a transaction on Tuesday, April 8th. The shares were purchased at an average price of $1.32 per share, for a total transaction of $66,000.00. Following the completion of the acquisition, the director now directly owns 91,207 shares in the company, valued at $120,393.24. This trade represents a 121.34% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 83,993 shares of company stock worth $118,224. 5.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of HUMA. Columbia Advisory Partners LLC purchased a new position in Humacyte during the 1st quarter worth $27,000. Hamilton Lane Advisors LLC purchased a new position in Humacyte during the 1st quarter worth $37,000. Letko Brosseau & Associates Inc. bought a new stake in Humacyte during the 1st quarter valued at $42,000. Petros Family Wealth LLC bought a new stake in Humacyte during the 4th quarter valued at $50,000. Finally, Syon Capital LLC bought a new stake in Humacyte during the 4th quarter valued at $54,000. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.